Temple, a preventive health and wearable technology startup backed by entrepreneur Deepinder Goyal, has acquired Longevous, a London-based medical practice specialising in longevity treatment. The deal marks Temple’s first move into an international market and gives the company a base in the UK health sector, from which it intends to expand further across Europe.
Temple is developing a wearable health monitor designed to be worn on the temple, reading and interpreting signals from the body to build a picture of a user’s physiological state over time. The device remains in a testing phase. It has not yet undergone independent scientific validation, and the company has not confirmed a date for commercial release.
Longevous had built a practice around extending healthspan rather than simply treating illness, using biomarker analysis to guide individually tailored lifestyle interventions. Its client base sat within the wider longevity medicine sector, a field that has grown steadily in London over the past several years as demand for preventive and personalised healthcare has increased among wealthier patients.
Under the terms of the acquisition, Longevous will be folded into Temple’s operations, and its two founders will take up senior roles within the enlarged company. Dr Robert Mohr, who trained originally in emergency medicine before moving into precision and longevity medicine, has been appointed Chief Medical Officer. His clinical background spans acute care and, more recently, the kind of preventive, data-driven medicine that underpins Longevous’s approach.
Dr Avi Roy, an Oxford-educated biomedical scientist, becomes Head of Science. Roy has worked across both the commercial and academic sides of the longevity field, a combination that Temple has said it wanted in-house as it moves closer to launching its device. His research background includes work on ageing biology, alongside experience advising longevity-focused companies on scientific strategy.
Goyal has said that bringing Mohr and Roy into Temple directly was intended to secure clinical and research credibility ahead of the product’s eventual launch. The company has framed the acquisition as a way of ensuring its device is developed alongside practising clinicians and scientists, rather than relying solely on internal engineering teams. Neither Temple nor Longevous has disclosed the financial terms of the transaction.
The move follows a pattern common among wearable and health-technology companies, which have increasingly sought to acquire clinical practices or hire medical staff directly as they attempt to establish scientific legitimacy before bringing consumer devices to market. Regulatory scrutiny of health claims made by wearable technology has intensified in recent years, and companies entering the space have faced pressure to demonstrate that their products are grounded in verifiable medical evidence.
For Temple, the acquisition provides an immediate presence in a market where Longevous was already operating and known to clients. The company is expected to spend the coming months working through the regulatory requirements attached to offering medical and longevity services in the UK, a process that will involve engagement with local health authorities as well as compliance with data protection and clinical governance rules that differ from those in Temple’s home market.
Temple has also indicated that it intends to pursue clinical partnerships in the region, working with hospitals, research institutions or private clinics to support further development and validation of its wearable device. Alongside this, the company plans to begin offering personalised health optimisation services to a broader base of European clients, extending beyond the smaller client group Longevous served before the acquisition.
No timeline has been given for when Temple’s wearable device will complete testing or become available to consumers. The company has said that further details on its product roadmap and European expansion plans will be released in the coming months.
